Donor Immune Cells Enter Cancer Trials as CytoMed Bets on Off-the-Shelf CAR-T Approach

The most compelling promise of cancer cell therapy is turning immune cells into precision weapons; the hardest reality to overcome, however, is often that a drug must be manufactured again for each individual patient. The approach being advanced by Singapore biotech company CytoMed Therapeutics focuses on “off-the-shelf” immune cells: using gamma delta T cells from healthy donors as the foundation, genetically engineering them, and applying them to treat cancer patients who have no blood relationship or matching relationship with the donor.

According to the company’s previous announcements and filings with the U.S. Securities and Exchange Commission, CytoMed has completed dosing of the first patient in its first-in-human Phase 1 ANGELICA dose-escalation trial. The trial, registered as NCT05302037, is evaluating the candidate therapy CTM-N2D, an allogeneic CAR gamma delta T cell targeting NKG2D ligands, in patients including those with advanced solid tumors or hematologic malignancies.

The key here is not only the three letters CAR-T, but the source of the cells. Traditional CAR-T mostly extracts T cells from the patient’s own blood, modifies them, and then infuses them back; the process is highly personalized and is also easily constrained by the patient’s condition, cell quality, manufacturing time, and cost. CytoMed argues that gamma delta T cells can be obtained from the blood of qualified donors, manufactured, and infused into unrelated patients, without requiring donor-patient compatibility matching in the usual sense, and therefore may be better suited for development toward a stockable and scalable product model.

The trial began in Singapore and received clinical trial authorization from Singapore’s Health Sciences Authority. The company also said in October 2024 that the ANGELICA trial was jointly supported by a clinical trial grant from the National Medical Research Council under Singapore’s Ministry of Health and MOH Holdings, and was being conducted in collaboration with National University Hospital Singapore. This information shows that the program is not simply a laboratory concept, but has entered the stage of regulated human safety evaluation.

However, the significance of a Phase 1 trial is mainly to confirm safety, tolerability, and dose, not to prove that a treatment can rewrite cancer care. Although allogeneic cell therapy has the opportunity to lower manufacturing barriers, it still must answer several core questions: whether the engineered cells can survive long enough in patients, whether they will trigger unacceptable immune reactions, whether their effects are consistent across different tumor types, and whether quality remains stable after large-scale manufacturing.

The NKG2D ligand approach itself also needs to be interpreted cautiously. Many cancer cells express stress signals that can be recognized by NKG2D, making it an immunotherapy target; but the tumor microenvironment often suppresses immune cell function, and solid tumors also present challenges such as insufficient infiltration, antigen heterogeneity, and immune escape. In other words, a rational target does not equal clinical effectiveness, and early trial data will be more persuasive than the platform narrative.

From an industry perspective, CytoMed’s progress reflects that Asian biotech companies are also pursuing manufacturing answers for next-generation cell therapies. If off-the-shelf CAR gamma delta T cells can establish themselves on safety and preliminary efficacy, they may in the future improve the speed and cost of patient access to cell therapy; if the clinical signals are not clear enough, it will also remind the market that innovation in cell source is only the starting point, and the real barrier remains the immunobiology inside the human body.